1. Introduction {#sec1}
===============

Coronaviruses are enveloped non-segmented positive-sense RNA viruses belonging to the family Coronaviridae, with a genome ranging from 26 to 32 kilobases in length \[[@bib1]\]. Among the several coronaviruses that are pathogenic to humans, most are associated with mild clinical symptoms, with two notable exceptions: severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) \[[@bib2],[@bib3]\], which have caused more than 10000 cumulative cases in the past two decades with mortality rates of 9.5% and 34.4% respectively \[[@bib4], [@bib5], [@bib6]\]. In December 2019, a novel pneumonia, termed coronavirus disease 2019 (COVID-19), emerged in Wuhan, China and has been proven to be caused by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) \[[@bib7]\]. All the twenty-seven first cases reported by December 31, 2019 were closely related to exposure with the Huanan Seafood Market in Wuhan \[[@bib8]\]. By analyzing the genome sequence of SARS-CoV-2, it was speculated that the pathogen originated in bat, the natural reservoir host, and then transmitted to humans via an uncertain wild animal intermediate host \[[@bib9]\]. There is convincing evidence that the human-to-human transmission has occurred since the end of December 2019 or the early January 2020 \[[@bib10]\]. To control the spread of COVID-19, the Wuhan authority has sealed off the entire city from outside contact since Jan 23, 2020. However, it\'s estimated that five million people have left Wuhan before the "lockdown" and travelled throughout China \[[@bib11]\]. By April 1, 2020, the disease has affected over 200 countries, with over 880,000 confirmed cases and 44220 deaths \[[@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18]\]. In China, substantial attention has focused mainly on Wuhan, whereas the detailed information regarding the disease outside Wuhan is rarely reported \[[@bib19],[@bib20]\]. Furthermore, little is known about the changes in pathogenicity, clinical manifestations and mode of transmission of SARS-CoV-2 when the epidemic expanded beyond Wuhan.

Here, we summarized the epidemiologic and clinical characteristics of 20 laboratory-confirmed cases of COVID-19 in Guangdong who hospitalized in the 3rd affiliated hospital of Sun Yat-sen University from January 22 to February 18, 2020, and compared these cases with previous reported cases in Wuhan, aiming to provide information for understanding the changes in clinical manifestations and transmission model.

2. Methods {#sec2}
==========

2.1. Study design and participants {#sec2.1}
----------------------------------

The study was approved by the Third Affiliated Hospital of Sun Yat-Sen University Ethics Committee, and oral consent was obtained from patients. All confirmed patients with COVID-19 admitted to the Third Affiliated Hospital of Sun Yat-Sen University from Jan 22 to Feb 12, 2020 were enrolled and followed-up until February 18, 2020. All patients with COVID-19 enrolled in this study were diagnosed according to the WHO interim guidance \[[@bib21]\]. To compare the epidemiological and clinical characteristics between patients in Guangdong and Wuhan (epidemic area), we included previously published data on 99 cases diagnosed in Wuhan Jinyintan Hospital from January 1 to January 20, 2020. Wuhan patients were followed-up until January 25, 2020 \[[@bib22]\].

2.2. Data collection {#sec2.2}
--------------------

The epidemiological characteristics (including recent exposure history), clinical symptoms and signs, radiologic and laboratory findings were extracted from electronic medical records. Radiologic assessments included chest X-ray or computed tomography (CT). Laboratory assessments consisted of complete blood count, blood chemistry, coagulation test, liver and renal function, electrolytes, C-reactive protein (CRP), procalcitonin (PCT), lactate dehydrogenase and creatine kinase. ARDS was defined according to the Berlin definition \[[@bib23]\].

2.3. Laboratory confirmation of SARS-Cov-2 infection {#sec2.3}
----------------------------------------------------

The viral nucleic acid testing-based laboratory confirmation of SARS-CoV-2, performed by the hospital\'s laboratory and the key laboratory of Guangdong Centre for Disease Control and Prevention (CDC), China, was determined by real-time RT-PCR according to the Chinese national CDC recommended protocol. Firstly, the nasopharyngeal swab was collected every 2 days during hospitalization. Then the RNA samples from the nasal swab specimens were extracted and subjected to the real-time RT-PCR test using SARS-Cov-2 specific primers and probes. Specifically, the primers for the open reading frame 1 ab (ORF1ab) are 5′-CCCTGTGGGTTTTACACTTAA-3\' (Forward) and 5′-ACGATTGTGCATCAGCTGA-3\' (Reverse); the corresponding probe is 5′-CY3-CCGTCTGCGGTATGTGGAAAGGTTATGG-BHQ1-3′. Primers for nucleocapsid protein (N) are 5′-GGGGAACTTCTCCTGCTAGAAT-3\' (Forward) and 5′-CAGACATTTTGCTCTCAAGCTG-3\' (Reverse); the corresponding probe is 5′-FAM-TTGCTGCTGCTTGACAGATT-TAMRA-3′. The clearance of SARS-CoV-2 was defined as two consecutive negative results with qPCR detection at an interval of 24 h.

2.4. Statistical analysis {#sec2.4}
-------------------------

Continuous variables were expressed as mean (SD) or median (IQR) and compared with the *t*-test or Mann-Whitney *U* test; categorical variables were expressed as frequency (%) and compared by χ^2^ test or Fisher\'s exact test between the cases in Guangzhou and Wuhan. For laboratory indicators, we categorized the results into normal or abnormal (increased or decreased). We used SPSS (IBM, version 26.0) for all analyses.

2.5. Role of the funding source {#sec2.5}
-------------------------------

Funding sources had no role in this study. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

3. Results {#sec3}
==========

3.1. Demographics, baseline characteristics and clinical characteristics {#sec3.1}
------------------------------------------------------------------------

All the COVID-2019 patients (N = 20) admitted in the Third Affiliated Hospital of Sun Yat-sen University were enrolled, including 10 males and 10 females. Patients in Guangzhou were younger than those in Wuhan (43.2 vs 55.5 years, *P* \< 0.001). Among Guangzhou patients, 14 had a history of living or travelling in Wuhan, and 6 were local incident patients with a history of close contact with confirmed cases. 10 Guangzhou patients were from seven clusters, including five family clusters, one cruise ship cluster and one driving tour cluster to Wuhan, while only two shoppers were community clustered among Wuhan patients.

Patients in both cities mainly manifested fever, cough and myalgia. Cough (82% vs 55%, *P* = 0.017) and shortness of breath (31% vs 10%, *P* = 0.052) were more prevalent among patients in Wuhan, while patients in Guangzhou had a higher prevalence of diarrhea (2% vs 25%, *P* = 0.001) and vomiting (1% vs 15%, *P* = 0.015). Higher percentages of patients were admitted to the ICU (23% vs 5%, *P* = 0.072) and complications (33% vs 15%, *P* = 0.118), such as ARDS (17% vs 1%, *P* = 0.302) in Wuhan ([Table 1](#tbl1){ref-type="table"} ).Table 1Baseline characteristics and epidemiology of patients with COVID-19 within and outside Wuhan.Table 1Guangzhou^\#1^ (N = 20)Wuhan^\#2^ (N = 99)*P* values**Characteristics**Age, years, Mean (SD)43.2 (14.0)55.5 (13.1)\<0.001 Range25--6421--82 ≤399 (45.0%)10 (10.1%)0.002 40-494 (20.0%)22 (22.2%) 50-592 (10.0%)30 (30.3%) 60-695 (25.0%)22 (22.2%) ≥700 (0.0%)15 (15.2%)Sex0.198 Female10 (50.0%)32 (32.3%) Male10 (50.0%)67 (67.7%)Chronic medical illness7 (35.0%)50 (50.5%)0.229 Cardiovascular and cerebrovascular diseases5 (25.0%)40 (40.4%)0.209 Digestive system disease3 (15.0%)11 (11.1%)0.703 Endocrine system disease1 (5.0%)13 (13.1%)0.460 Malignant tumor0 (0.0%)1 (1.0%)1.000 Respiratory system disease1 (5.0%)1 (1.0%)0.309 Admission to intensive care unit1 (5.0%)23 (23.2%)0.072**Signs and symptoms**Fever16 (80.0%)82 (82.8%)0.752Cough11 (55.0%)81 (81.8%)0.017Shortness of breath2 (10.0%)31 (31.3%)0.052Myalgia7 (35.0%)11 (11.1%)0.013Sore throat4 (20.0%)5 (5.1%)0.043Diarrhea5 (25.0%)2 (2.0%)0.001Nausea and vomiting3 (15.0%)1 (1.0%)0.015More than one sign or symptom18 (90.0%)89 (89.9%)1.000Fever, cough, and shortness of breath2 (10.0%)15 (15.2%)0.734**Comorbid conditions**Any3 (15.0%)33 (33.3%)0.118 ARDS1 (5.0%)17 (17.2%)0.302 Acute renal injury0 (0.0%)3 (3.0%)1.000 Acute respiratory injury1 (5.0%)8 (8.1%)1.000 Septic shock1 (5.0%)4 (4.0%)1.000 Ventilator-associated pneumonia0 (0.0%)1 (1.0%)1.000**Epidemiological survey**Exposure to Huanan seafood market0 (0.0%)49 (49.5%)\<0.001Live history in epidemic area[a](#tbl1fna){ref-type="table-fn"}14 (70.0%)99 (100.0%)\<0.001Community cluster outbreak10 (50.0%)2 (2.0%)^\#3^\<0.001Close contacts with COVID-19 patient6 (30.0%)NANA[^3][^4][^5][^6][^7]

3.2. Laboratory, imaging, and pathogenic characteristics of patients with COVID-19 {#sec3.2}
----------------------------------------------------------------------------------

Blood routine and biochemical data of the patients in Guangzhou were basically normal, and only 25% of the patients had a lymphocyte count of less than 1.0 × 10^9^/L. The lymphocyte count, hemoglobin and albumin of patients in Wuhan were significantly lower, while inflammatory biomarkers, blood erythrocyte sedimentation rate (ESR), CRP and PCT were significantly higher than those in Guangzhou (all *P* values \< 0.05). Chest CT scan indicated bilateral involvement in both cities. Based on Guangzhou data, the main manifestations were multiple patches (90%), ground-glass opacity (80%) and interstitial lesions (80%). Invasive lesions were presented in 55% of patients ([Fig. 1](#fig1){ref-type="fig"} ). Multiple mottling and ground-glass opacity were more common in Guangzhou patients (14% vs 60%, *P* \< 0.001) ([Table 2](#tbl2){ref-type="table"} ).Fig. 1**Dynamic changes of CT images in a 37-year-old man who confirmed COVID-19.** Axial thin-section non-contrast CT scan shows bilateral multiple lobular ground-glass opacities progressed from day 4 to day 7 from onset. The non-contrast CT of day 14 and day 17 shows that bilateral lobular ground-glass opacities resolved gradually.Fig. 1Table 2Comparison of Laboratory data and Outcome of Patients with COVID-19 Within and Outside Wuhan.Table 2Guangzhou^\#1^ (N = 20)Wuhan^\#2^ (N = 99)*P* values**Blood routine**Leucocytes ( × 10^9^/L, normal range 3.5--9.5)5.2 (1.6)7.5 (3.6)0.006Lymphocytes ( × 10^9^/L, normal range 1.1--3.2)1.4 (0.7)0.9 (0.5)0.003Platelets ( × 10^9^/L, normal range 125.0--350.0)205.0 (62.6)213.5 (79.1)0.652Hemoglobin (g/L, normal range 130.0--175.0)139.3 (15.3)129.8 (14.8)0.010**Blood biochemistry**Increased alanine aminotransferase4 (20.0%)28 (28.3%)0.584Increased aspartate aminotransferase3 (15.0%)35 (35.4%)0.113Increased total bilirubin1 (5.0%)18 (18.2%)0.192Albumin (g/L)44.8 (5.6)31.6 (4.0)\<0.001 Decreased1 (5.0%)97 (98.0%)\<0.001Increased serum creatinine1 (5.0%)3 (3.0%)0.526Increased creatine kinase5 (25.0%)13 (13.1%)0.183Increased myoglobin2/17 (11.8%)15 (15.2%)1.000**Infection-related biomarkers**Erythrocyte sedimentation rate (mm/h, normal range 0--15)19.3 (13.2)49.9 (23.4)\<0.001C-reaction protein (mg/L, normal range 0--6)25.0 (29.3)51.4 (41.8)0.002Procalcitonin (ng/mL, normal range 0--0.05)0.08 (0.09)0.5 (1.1)\<0.001**Chest X-ray and CT finding**Unilateral pneumonia2 (10.0%)25 (25.3%)0.239Bilateral pneumonia18 (90.0%)74 (74.7%)0.239Multiple mottling and ground-glass opacity12 (60.0%)14 (14.1%)\<0.001Peripheral pneumonia17 (85.0%)NANAinterstitial lesions16 (80.0%)NANAGround-glass opacity16 (80.0%)NANAMultiple patches18 (90.0%)NANAMultiple Infiltration11 (55.0%)NANANodule4 (20.0%)NANALung consolidation4 (20.0%)NANAPleural effusion2 (10.0%)NANA[^8][^9][^10][^11]

3.3. Treatment and prognosis of patients with COVID-19 {#sec3.3}
------------------------------------------------------

In both cities, most patients were mainly treated with antibiotics or antivirus therapy, including Lopinavir and Ritonavir (Kaletra), arbidol, ribavirin and aerosol inhalation of interferon alpha, 13 (65%) patients were given combination antivirus therapy (data only available in Guangzhou patients) ([Table 3](#tbl3){ref-type="table"} ). 27%--30% of patients were treated with immunoglobulin and 20% with thymosin alpha-1 (data only available in Guangzhou patients) to regulate immunity. 25% of patients in Guangzhou, compared to 19.2% in Wuhan, with severe pulmonary inflammation and decreased oxygenation index received short-term corticosteroids treatment, with methylprednisolone 1 mg/kg/day for 3 days. More patients in Wuhan needed oxygen treatment than those in Guangzhou (75% vs 40%, *P* = 0.001). By the last follow-up date, the patients in Guangzhou have a higher discharged rate and lower mortality rate than those in Wuhan (*P* = 0.005).Table 3Treatment and prognosis of patients with COVID in Guangzhou and Wuhan.Table 3Guangzhou^\#1^ (N = 20)Wuhan^\#2^ (N = 99)*P* value**Treatment**Oxygen therapy8 (40.0%)75 (75.8%)0.001Mechanical ventilation2 (10.0%)17 (17.2%)0.738 Non-invasive (ie, face mask)1 (5.0%)13 (13.1%)0.460 Invasive1 (5.0%)4 (4.0%)1.000CRRT0 (0.0%)9 (9.1%)0.354ECMO0 (0.0%)3 (3.0%)1.000Antiviral therapy16 (80.0%)75 (76.0%)0.781 Kaletra\*16 (80.0%)NANA Arbidol13 (65.0%)NANA Interferon alpha atomized inhalation5 (25.0%)NANA Ribavirin1 (5.0%)NANA Combination of two antiviral drugs9 (45.0%)NANA Combination of three antiviral drugs4 (20.0%)NANAAntibiotic therapy17 (85.0%)70 (70.7%)0.271Glucocorticoids5 (25.0%)19 (19.2%)0.550Intravenous immunoglobulin therapy6 (30.0%)27 (27.3%)0.789Thymosin alpha14 (20.0%)NANAChinese traditional medicine20 (100.0%)NANA**SARS-CoV-2 RNA positive at admission**Nasopharyngeal swabs20 (100.0%)99 (100.0%)1.000Feces (n/N, %)4/7 (57.1%)NANA**Duration of SARS-CoV-2 RNA positive**Nasopharyngeal swabs (N = 20) (days)12.0 (7.5, 15.5)NANAFeces (N = 4 of 7) (range, days)4.0--16.0NANA**Clinical outcome** Outcome0.005 Remained in hospital6 (30.0%)57 (57.6%) Discharged14 (70.0%)31 (31.3%) Died0 (0.0%)11 (11.1%)[^12][^13][^14][^15]

3.4. SARS-CoV-2 RNA in nasopharyngeal swabs and feces {#sec3.4}
-----------------------------------------------------

Among Guangzhou patients, SARS-CoV-2 RNA in nasopharyngeal swabs disappeared at an average of 12 days (maximum, 22 days). SARS-CoV-2 RNA in feces turned negative in 4--16 days. In two cases, the fecal RNA did not turn negative until 5 and 6 days after negative nasopharyngeal swab.

4. Discussion {#sec4}
=============

By comparing cases from the Third Affiliated Hospital of Sun Yat-sen University between January 22 to February 18, 2020 and Wuhan Jinyintan Hospital between January 1 to January 25, 2020, this study revealed the changes in pathogenicity and epidemic characteristics of COVID-19 in the epidemic process. Both hospitals are designated hospital for COVID-19. Although small in number, the Guangzhou patients were a random sample at an early stage when cases started being imported into a major city. The different admission time in the two hospitals could represent two stages of the epidemic, while treatment and follow-up time are the same, which may well reflect the changing clinical and epidemiological characteristics of the disease.

The median ages of cases in Wuhan reported by Cao and Zhang were 49.0 and 55.5 years respectively^8,22^, while patients in Guangzhou were relatively younger, with the median age of 43.2 years. There have been reports of cases in children, indicating all ages are susceptible \[[@bib24]\]. Compared with patients in Guangzhou, patients in Wuhan were more severe, reflected by that Wuhan patients had a higher incidence of dyspnea and ARDS, higher levels of inflammatory biomarkers and worse prognosis. These differences could be due to age and pre-existing conditions \[[@bib8],[@bib25],[@bib26]\]. However, in the present study, we did not observe an evident difference in underlying disease between Guangzhou patients and Wuhan patients. We speculate that the differences may be related to that the diminishing pathogenicity of the virus after transmission of multiple generations \[[@bib5],[@bib27]\], however, further studies are required to confirm this hypothesis. Besides, patients in Guangzhou were more aware of the disease; thus, they visited the hospital at the earlier stage with less severe symptoms. Furthermore, given the experience in Wuhan, the health authorities in Guangzhou were well-prepared for the epidemic and were able to carry out comprehensive screening, early case identification and contact tracing and timely treatment.

In terms of clinical characteristics, we observed that the gastrointestinal symptoms such as diarrhea and vomiting were more prevalent in patients with later-onset in Guangzhou. Meanwhile, fecal RNA was positive in 4 out of 7 patients, indicating the possibility of gastrointestinal transmission. Xiao Fei also confirmed gastrointestinal infection by detecting SARS-CoV-2 in feces and gastrointestinal tissues \[[@bib28]\]. These findings have important implications for patient triage and hospital risk zoning. Gastroenterology outpatient medical staff could be at higher risk when encountering COVID patients, thus more aggressive PPE protection and proactive patient screening are necessary. In addition, sufficient education and protocols should be given to caregivers who could be exposed to the patients\' vomits and feces directly, and feces disposal should be managed properly to reduce environmental harzards. More importantly, we found that two patients' fecal virus RNA turned negative 5 and 6 days later than the nasopharyngeal swab respectively, suggesting that transimission of virus is possibly prolonged, and fecal virus RNA may be an indispensable indicator for lifting quarantines. Given that some "recovered" cases being tested positive again a few days after discharged have been reported recently \[[@bib29]\], our findings highlight the importance of fecal virus test for patient management and quarantines. The health authority may also have to re-consider quarantine strategy for possible extended case management time and burden when distributing health resources.

Our findings also suggest that the modes of transmission have changed considerably with the spread of the disease. A large fraction of early reported cases in Wuhan were linked to Huanan seafood markets, whereas none of cases in Guangzhou had a history of exposure to wildlife markets. Furthermore, 10 patients from Guangzhou were involved in seven cases of clustering. This finding suggests strong community transmission poses a great challenge to the entire prevention and control. It resonates with the concept that the transmissibility increases while virulence decreases as virus spread \[[@bib30]\]. As indicated by Tang\'s research, the L type of SARS-CoV-2 prevalent in the early stages of the outbreak in Wuhan, decreased after early January 2020, while the S type, which is less aggressive, have increased in relative frequency due to relatively weaker selective pressure \[[@bib31]\]. Thus early detection and timely isolation is vital before a case becomes a cluster. It also raises the concern that the risk and benefit should be balanced in home quarantine for confirmed cases which could result in family case clusters.

At present, symptomatic, support treatment and airway maintenance are the main treatments, as there is no proven effective antiviral therapy. It is claimed that kaletra, remdesivir and chloroquine phosphate have antiviral effects from preliminary studies \[[@bib32],[@bib33]\], but the results of clinical trials are yet to be released. Patients in Guangzhou mainly use kaletra + arbidol, some with severe pulmonary inflammation added interferon atomized inhalation, which has also achieved good treatment effect. Nevertheless, further research with control groups would be helpful to differentiate whether the effect is caused by drugs or patients' self-recovery of the disease.

Our study has limitations. First, the number of patients was small. Second, Wuhan cases are from published data, and more detailed information, such as the final prognosis of patients, could not be obtained.

In summary, our results suggest that the virulence of SARA-CoV-2 is possibly waning in the process of transmission and the clustering occurrence is becoming the primary model of transmission. In addition, our observation that fecal virus RNA turned negative later than the nasopharyngeal swab justifies that the concern of faecal-oral transmission and suggest that fecal virus RNA should be assessed before lifting quarantine.
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